ChristopherFlintO'BrienMD

PubMed

• 1 citations
  A long-term, open-label study of valbenazine for tardive dyskinesia.
  Jean-Pierre Lindenmayer, Cherian Verghese, Stephen R. Marder, Joshua Burke, Roland Jimenez, Scott Siegert, Grace S. Liang, Christopher F. O'Brien> ;CNS Spectrums. 2021 Aug 1
• 17 citations
  A Phase 3, 1-Year, Open-Label Trial of Valbenazine in Adults With Tardive Dyskinesia
  Stephen R. Marder, Carlos Singer, Jean-Pierre Lindenmayer, Caroline M. Tanner, Cynthia L. Comella, Cherian Verghese, Roland Jimenez, Grace S. Liang, Joshua Burke, Chri...> ;Journal of Clinical Psychopharmacology. 2019 Nov 1
• 15 citations
  Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference
  Mark Stacy, Martha Sajatovic, John M. Kane, Andrew J. Cutler, Grace S. Liang, Christopher F. O'Brien, Christoph U. Correll> ;Movement Disorders. 2019 Jun 24
• 64 citations
  The Effects of Valbenazine in Participants with Tardive Dyskinesia: Results of the 1-Year KINECT 3 Extension Study.
  Stewart A. Factor, Gary Remington, Cynthia L. Comella, Christoph U. Correll, Joshua Burke, Roland Jimenez, Grace S. Liang, Christopher F. O'Brien> ;The Journal of Clinical Psychiatry. 2017 Nov 14
• 19 citations
  Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.
  Richard C Josiassen, John M. Kane, Grace S. Liang, Joshua Burke, Christopher F. O'Brien> ;Psychopharmacology Bulletin. 2017 Aug 1
• 15 citations
  Single Dose and Repeat Once-Daily Dose Safety, Tolerability and Pharmacokinetics of Valbenazine in Healthy Male Subjects
  Rosa Luo, Haig Bozigian, Roland Jimenez, Gordon Loewen, Christopher F. O'Brien> ;Psychopharmacology Bulletin. 2017 Aug 1
• 13 citations
  Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Mood Disorder.
  Christoph U. Correll, Richard C Josiassen, Grace S. Liang, Joshua Burke, Christopher F. O'Brien> ;Psychopharmacology Bulletin. 2017 Aug 1
• 16 citations
  Efficacy of Valbenazine (NBI-98854) in Treating Subjects with Tardive Dyskinesia and Schizophrenia or Schizoaffective Disorder.
  John M. Kane, Christoph U Correll, Grace S. Liang, Joshua Burke, Christopher F. O'Brien> ;Psychopharmacology Bulletin. 2017 Aug 1
• 147 citations
  KINECT 3: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Trial of Valbenazine for Tardive Dyskinesia
  Robert A. Hauser, Stewart A. Factor, Stephen R. Marder, Mary Ann Knesevich, Paul Michael Ramirez, Roland Jimenez, Joshua Burke, Grace S. Liang, Christopher F. O'Brien> ;The American Journal of Psychiatry. 2017 Mar 21
• 32 citations
  Elagolix, an oral GnRH antagonist for endometriosis-associated pain: a randomized controlled study
  Bruce R. Carr, Linda C. Giudice, W. Paul Dmowski, Christopher F. O'Brien, Ping Jiang, Joshua Burke, Roland Jimenez, Steven Hass, Mahesh Fuldeore, Kristof Chwalisz> ;Journal of Endometriosis and Pelvic Pain Disorders. 2013 Jul 13
• 45 citations
  A pharmacokinetic evaluation of five H1 antagonists after an oral and intravenous microdose to human subjects
  Ajay Madan, Zhihong O’Brien, Jianyun Wen, Christopher F. O'Brien, Robert Farber, Graham Beaton, Paul D. Crowe, B. Oosterhuis, R. Colin Garner, Graham Lappin, Haig Bozi...> ;British Journal of Clinical Pharmacology. 2009 Mar 1
• 8 citations
  R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation
  William C. Nichols, Diane K. Marek, Michael W. Pauciulo, Nathan Pankratz, Cheryl Halter, Alice Rudolph, Clifford W. Shults, Joanne Wojcieszek, Tatiana Foroud, Cliff Sh...> ;Movement Disorders. 2007 Jan 15
• 25 citations
  Mutations in LRRK2 other than G2019S are rare in a north-American based sample of familial Parkinson's didease
  Nathan Pankratz, Michael W. Pauciulo, V. E. Elsaesser, Diane K. Marek, Cheyl A. Halter, Alice Rudolph, Clifford W. Shults, Tatiana Foroud, William C. Nichols, Cliff Sh...> ;Movement Disorders. 2006 Dec 1
• 86 citations
  Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia.
  Nathan Pankratz, Lisa Byder, Cheryl Halter, Alice Rudolph, Clifford W. Shults, P. Michael Conneally, Tatiana Foroud, William C. Nichols, Kelly E. Lyons, Karen Marder, ...> ;Movement Disorders. 2006 Jan 1
• 39 citations
  Relapse rates and enhancing lesions in a phase II trial of natalizumab in multiple sclerosis
  Paul O'Connor, David Miller, Katherine Riester, Minhua Yang, Michael Panzara, Catherine M. Dalton, Katherine A. Miszkiel, Omar Khan, George Rice, William A. Sheremata,...> ;Multiple Sclerosis. 2005 Oct 1
• 56 citations
  Interrater agreement in the assessment of motor manifestations of Huntington's disease
  Penelope Hogarth, Elise Kayson, Karl Kieburtz, Karen Marder, David Oakes, Diana Rosas, Ira Shoulson, Nancy S. Wexler, Anne B. Young, Hongwei Zhao, Charles H. Adler, Ro...> ;Movement Disorders. 2005 Mar 1
• 27 citations
  Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease
  William C. Nichols, Sean K. Uniacke, Nathan Pankratz, Terry Reed, David Simon, Cheryl Halter, Alice Rudolph, Clifford W. Shults, P. Michael Conneally, Tatiana Foroud, ...> ;Movement Disorders. 2004 Jun 1
• 100 citations
  Significant Linkage of Parkinson Disease to Chromosome 2q36-37
  Nathan Pankratz, William C. Nichols, Sean K. Uniacke, Cheryl Halter, Alice Rudolph, Cliff Shults, P. Michael Conneally, Tatiana Foroud, Lawrence I. Golbe, William C. K...> ;American Journal of Human Genetics. 2003 Apr 1
• 167 citations
  Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease
  Tatiana Foroud, Sean K. Uniacke, L. Liu, Nathan Pankratz, Anja Rudolph, Cheryl Halter, Clifford W. Shults, Karen Marder, P. M. Conneally, William C. Nichols, Lawrence ...> ;Neurology. 2003 Mar 11
• 64 citations
  Speech Loudness and Quality 12 Months after Intensive Voice Treatment (LSVT®) for Parkinson’s Disease: A Comparison with an Alternative Speech Treatment
  Shimon Sapir, Lorraine O. Ramig, Patricia Hoyt, Stefanie Countryman, Christopher F. O'Brien, Margaret M. Hoehn> ;Folia Phoniatrica Et Logopaedica. 2002 Nov 6
• 55 citations
  Treatment of spasticity with botulinum toxin.
  Christopher F O'Brien> ;The Clinical Journal of Pain. 2002 Nov 1
• 48 citations
  Reliability of measurements of patient health status: a comparison of physician, patient, and caregiver ratings
  Cynthia McRae, Gretchen Diem, Alexander H. Vo, Christopher F. O'Brien, Lauren Seeberger> ;Parkinsonism & Related Disorders. 2002 Jan 1
• 25 citations
  Cervical dystonia severity scale reliability study.
  Christopher F. O'Brien, Allison Brashear, Paul A. Cullis, Daniel D. Truong, Eric Molho, Stephen Jenkins, Joanne Wojcieszek, Thomas O'Neil, Stewart A. Factor, Lauren Se...> ;Movement Disorders. 2001 Nov 1
• 269 citations
  Intensive voice treatment (LSVT®) for patients with Parkinson's disease: a 2 year follow up
  Lorraine O. Ramig, Shimon Sapir, Stefanie Countryman, A A Pawlas, Christopher F. O'Brien, Margaret M. Hoehn, L L Thompson> ;Journal of Neurology, Neurosurgery, and Psychiatry. 2001 Oct 1
• 101 citations
  The natural history of embouchure dystonia.
  Steven J. Frucht, Stanley Fahn, Paul Greene, Christopher F. O'Brien, Michael Gelb, Daniel D. Truong, John P. Welsh, Stewart A. Factor, Blair Ford> ;Movement Disorders. 2001 Sep 1
• Join now to see all